Discover more from Geoff Pain PhD
Lymphadenopathy Danger from Endotoxin in Pfizer Jabs
There was a Clear and Present Danger Signal as soon as Pfizer went to Process 2. Pfizer uses 49 types of "Swelling" as "Preferred Terms" to hide Lymphatic damage
BioNTech/Pfizer and complicit marketers of their Covid19 jab, including government departments around the globe, lied to the public when the said that the Lipid NanoParticles and the mRNA floating inside or outside them, would simply enter muscle cells in the arm, take them over to force them to become factories for Synthetic Spike generation and resultant anti-Spike antibodies.
Robert Kogon published photosfrom a lecture given by one of the BioNTech founders in which it is clear that the actual target of the jab contents is the Draining Lymph Nodes and the wider Lymphatic System, including the Spleen. Note the heading of this slide showing how the jabs are actually intended to work.
A memorable quote: "Indeed, Sahin and Türeci were so determined to get their mRNA into the Lymph Nodes that they had an earlier mRNA construct injected directly into the patient's Lymph Nodes in the groin".
Once the mass jabbing began, others associated with the Pfizer jabbing design were quite straight with the intended action of the jab on the Lymphatic System.
In an interview of September 2021, Professor Drew Weissman, said:
LNPs encapsulate the mRNA, protecting it from extracellular degradation, and facilitate endosomal release of the mRNA into the cytoplasm. When the LNP-Ψ-mRNA is injected into the muscle, every cell takes it up, but for muscle cells that is very inefficient, you can barely measure the protein that they make. The LNPs are 80nm in size, which is about the size of a virus. What happens is that the LNPs travel through the lymphatic drainage to lymph nodes, and in the lymph nodes, DCs take them up. There is also an infiltrate of lymphoid cells into the muscle that picks up the particles. Once the vaccine gets to a lymph node, the DC translates the mRNA and presents it to B and T cells to activate them, and that is how the immune response is started.
From the Pfizer Clinical Trial, it was known that Lymphadenopathywas a small scale problem caused by their mRNA jabs made with Process 1, but there was an explosion of cases when they moved to Process 2 due to the Endotoxin from the E Coli bacteria used in production. As expected, the Lymphadenopathy is usually detected on the side of the body that received the jab. There have been previous alerts to the fact that Lymphadenopathy was caused by the jabs, but not the virus.
Paul Alexanderand Steve Kirsch listed large numbers of jab induced Lymphadenopathy studies to May 2022.
Lymphadenopathy in the Process 1 Trial
Quoting from a Trial documentobtained from the UK government (page 140)
Geoff Pain PhD is a reader-supported publication. Please consider a donation by upgrading to a paid subscriber.
Lymphadenopathy is identified as an adverse reaction for BNT162b2 vaccine.
During the blinded placebo-controlled follow-up period, 9 and 2 participants in theBNT162b2 and placebo groups reported AEs of lymphadenopathy, respectively (Table 44).
That is about 0.041 % of the roughly 22,000 who got Process 1 jab.
The numbers increased in a follow-up study to 1 month after Dose 2 of Process 1 jab.
Lymphadenopathy: in the BNT162b2 group, 64 participants (0.3 %) reported an AE of lymphadenopathy (54 in the younger age group and 10 in the older age group), and 6 in the placebo group. In cases where location was specified, lymphadenopathy occurred in the arm and neck region. Most lymphadenopathy events were reported within 2 to 4 days after vaccination. The mean duration was 10 days and 12 events were ongoing at the time of the data cut-off date. A total of 47 out of these 64 lymphadenopathy events were judged by the investigator as related to study intervention.
By the trial interim cut-off date of 14 November 2020, Pfizer reportedthe following data in Japan:
In the Phase II/III part of foreign Study C4591001, serious adverse events occurred in 126 of 21,621 subjects (0.6%) in the Comirnaty group and 111 of 21,631 subjects (0.5%) in the placebo group.
The incidence of lymphadenopathy was 0.3% (70 of 21,621 subjects) in the Comirnaty group and 0.0% (7 of 21,631 subjects) in the placebo group. Among these events, those in 50 subjects in the Comirnaty group and 4 subjects in the placebo group were considered related to the study vaccine. Lymphadenopathy mostly occurred in the arm or neck. Many of the events occurred within 2 to 4 days after study vaccination, but those in 12 subjects in the Comirnaty group and 3 subjects in the placebo group occurred ≥8 days after vaccination (98 days at the latest). One subject in the Comirnaty group experienced lymphadenopathy within 30 minutes of vaccination. The event in 1 subject in the Comirnaty group was serious and considered related to the study vaccine, with the outcome of “not recovered” (data cutoff date: November 14, 2020).
Lymphadenopathy in the Process 2 Rollout
I became aware of the massive Lymphadenopathy problem in Australia when I inspected the Database of Adverse Event Notifications
By 23 August 2021 there were 1,126 cases.
Australia’s TGA discussedthe massive increase in Trial participants who received the Process 2 Booster dose in October 2021.
Pfizer reported case numbers to April 2022.
Lymphadenopathy 73,287 = 5.44 % of all reports
Lymph node pain 8,395
Vaccination site lymphadenopathy 4,540
Also related are cases of Lymphadenopathy that can arise due to
Epstein-Barr virus infection reactivation 115
Epstein-Barr virus infection 109
Epstein-Barr virus antibody positive 26
Pfizer Update to 18 June 2022
An appendix to the Periodic Safety Update Report 3, obtained by FOI covers cumulative cases to 18 June 2022
It lists the following case numbers:
Haemophagocytic Lymphohistiocytosis 95
Abdominal Lymphadenopathy 41
Hilar Lymphadenopathy 40
Lymphadenopathy Mediastinal 60
Lymphatic Disorder 55
Lymphatic Insufficiency 3
Lymphatic Obstruction 6
Lymph Node Calcification 1
Lymph Node Fibrosis 2
Lymph Node Haemorrhage 4
Lymph Node Pain 9,199
Lymph Node Rupture 1
Lymph Node Ulcer 1
Lymphoid Tissue Hyperplasia 10
Necrotic Lymphadenopathy 11
Paratracheal Lymphadenopathy 13
Retroperperitoneal Lymphadenopathy 3
“Swelling” used to hide cases
In its June 2022 report, Pfizer uses 49 types of “Swelling” to help hide the true picture. In addition to the cases numbers above, the list:
Vaccination site swelling 39,932
Peripheral swelling 15,784
Swelling face 6,615
Joint swelling 4,150
Extensive swelling of vaccinated limb 3,610
Pharyngeal swelling 2,709
Breast swelling 1,478
Injection site swelling 757
Skin swelling 428
Vaccination site joint swelling 227
Muscle swelling 227
Bone swelling 129
Soft tissue swelling 122
Circumoral swelling 69
Oropharyngeal swelling 49
Genital swelling 35
Israel used to prove Lymphadenopathy Harms
In 2021 Cohen and coworkers reported a high incidence of Vaccine-Associated Hypermetabolic Lymphadenopathy (VAHL) in Axillary or Supraclavicular Lymph Nodes (ASLN) ipsilateral to the vaccination site. Lymphadenopathy was found in 36.4% of 1st jabbees, rising to 53.9% after the second jab. They used terms, Hypermetabolic Lymphadenopathy (HLN) and Equivocal HLN (EqHL).
In the huge Israel study by Barda and coworkers with the Vaccinated and Control groups each including a mean of 884,828 persons, Lymphadenopathy (Risk Ratio, 2.43; 95% CI, 2.05 to 2.78; Risk Difference, 78.4 events per 100,000 persons; 95% CI, 64.1 to 89.3) stood out as one of many harms of the Pfizer jab.
Lymphadenopathy 1 day after the Pfizer Jab
Case reports are scarce but here is the image of Lymphadenopathy imaged in the right breast of a woman one day after her Pfizer Covid19 jab.
Another Pfizer jab case of Lymphadenopathy was reported detected 3 days in a 72-year-old lady.Expensive imaging techniques are sometimes used to characterize such cases, including radiactive PET.
A surge in Lymphadenopathy cases was reported in the UK in 2021 and a variety of imaging techniques were used.
Lymphadenopathy rising with more Jabs
Previous Substack articles highlighted a paper where jab induced Lymphadenopathy was detected during mammograms and increased incidence with subsequent jabs.
Lymphadenopathy is recognized as one of many IgG4 Diseases caused by multiple jabbing.
Sato and coworkers have identified Lymphadenopathy among numerous IgG4 diseases.
14% Lymphadenopathy in Booster Complaints
Staggering that buried in an EMA document, we see 14% of people reporting Adverse Reaction to Pfizer Booster jabs suffered Lymphadenopathy.
Picograms of Endotoxin cause Lymphadenopathy
Endotoxemia researchers in Scotland found that the Odds Ratios (OR [95% CI]) for the occurrence of Splenomegaly and Cervical Lymphadenopathy were 1·19 [1·01–1·4] and 1·16 [1·02–1·35] respectively for every 10 picogram/mL increase in plasma Endotoxin concentration.
Breastfed Infants getting Lymphadenopathy
It would be useful to determine the jab date of the mother for 1 cases of a breastfed infant suffering Lymphadenopathy.
Lymphadenopathy related to CTLA-4 Deficiency
As mentioned in a recent post, Endotoxin can induce secretion of IL-10 that can act as either a pro-inflammatory of anti-inflammatory factor, depending on what other influences are operating.
Lauw and coworkersshowed that serum levels of Granzymes, proteins that are released from granules of activated CTL and NK cells and can trigger pathways of apoptosis in the target cells. They found GrA levels were transiently increased by exposure to Endotoxin. Increased plasma levels of soluble granzymes have been found in patients with Rheumatoid Arthritis, Epstein-Barr Virus, or HIV-1 infection.
Lymphadenopathy is a common symptom of CTLA-4 Deficiency, a rare disorder that severely impairs the normal regulation of the immune system, resulting in conditions such as Intestinal disease, Respiratory infections, Autoimmune problems, and Enlarged Lymph Nodes, Liver, and Spleen.
Jab Lymphadenopathy associated with Cancer
Reviews of the explosion of Lymphadenopathy have found incidences of Cancer Reactivation and Metastasis.Both reviews called for extra care in imaging interpretation, to distinguish reactive Lymph Nodes from Metastatic Lymph Node Enlargement, especially in patients with underlying malignancy.
Pfizer Booster jab was associated with rapid progression of Angioimmunoblastic T Cell Lymphoma.
Kikuchi-Fujimoto disease involves CD68 Histiocytes
Autopsy histology of mRNA jab induced Myocarditis victims has identified CD68 Histiocytes that I have reported are known to be upregulated by Endotoxin.
Certain types of Lymphadenopathy also involve CD68 cells. Kikuchi-Fujimoto disease is one type identified by staining histology.This figure from Hassan and coworkers shows the CD68 cells.
The long-term consequences of deliberate attack on the Human Lymphatic System could be tragic. The use of E coli to grow DNA code for synthetic mRNA must be stopped before more damage is done.
Kogon R. 2023. https://brownstone.org/articles/cdc-lied-mrna-not-meant-to-stay-in-arm/
Kogon R. 2023. https://www.sott.net/article/477249-The-CDC-lied-The-mRNA-wasnt-meant-to-stay-in-the-arm
Daniella Ruffell. 2021. The future in an RNA molecule: from mRNA vaccines to therapeutics – An interview with Drew Weissman. https://febs.onlinelibrary.wiley.com/doi/10.1002/1873-3468.14190
Treglia G, et al. 2021. PET findings after COVID-19 vaccination: “Keep Calm and Carry On”. https://link.springer.com/article/10.1007/s40336-021-00430-3
Interim Clinical Study Report Protocol C4591001. 2021. https://data.parliament.uk/DepositedPapers/Files/DEP2023-0138/Clinical_Study_Report_Part_2.pdf
Delegate’s Overview and Request for ACV’s Advice Active ingredient (s): BNT162b2 [mRNA] Proprietary Product Name: COMIRNATY COVID 19 vaccine Sponsor: Pfizer Australia Pty Ltd Submission number: PM-2020-05461-1-2 e-Submission ID: e005671
Comirnaty Intramuscular Injection_Pfizer Japan Inc._Report on Special Approval for Emergency in Report on the Deliberation Results February 12, 2021 Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau Ministry of Health, Labour and Welfare 18 Dec 2020.
Advisory Committee on Vaccines – Meeting 26 - Minutes - Comirnaty – BNT162b2 [mRNA] COVID-19 vaccine – Pfizer Australia Pty Ltd - PM-2021-04582-1-2 Date of Finalisation 26 October 2021
APPENDIX 2.1 Cumulative Number of Case Reports (Serious and Non-Serious, Medically Confirmed and Non Medically-Confirmed) from Post-Marketing Data Sources, Overall, by Sex, Country, Age Groups and in Special Populations and Summary Tabulation by Preferred Term and MedDRA System Organ Class BNT162B2 - ALL Reporting Period: Through 15-APR-2022
Cohen D, et al. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation. https://link.springer.com/article/10.1007/s00259-021-05314-2
Barda 2021. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. https://www.nejm.org/doi/full/10.1056/nejmoa2110475
Lam DL and Flanagan MR. 2021. Axillary Lymphadenopathy After COVID-19 Vaccination in a Woman With Breast Cancer. https://jamanetwork.com/journals/jama/fullarticle/2787650
Singh B, et al. 2021. COVID-19 vaccine induced Axillary and Pectoral Lymphadenopathy on PET scan. https://www.sciencedirect.com/science/article/pii/S1930043321002612
Brown A et al. 2021. Unilateral axillary adenopathy following COVID-19 vaccination: a multimodality pictorial illustration and review of current guidelines. https://www.clinicalradiologyonline.net/article/S0009-9260(21)00248-8/fulltext
Sato Y, et al. 2010. IgG4-related disease: historical overview and pathology of hematological disorders. https://onlinelibrary.wiley.com/doi/10.1111/j.1440-1827.2010.02524.x
Sato Y, et al. 2009. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease. https://www.sciencedirect.com/science/article/pii/S0893395222025388
European Medicines Agency Pharmacovigilance Risk Assessment Committee. Periodic Safety Update Report. Tozinamarem (Comirnaty) covering the period 19 December 2021 to 18 June 2022. Published January 2023.
Maclean L, et al. 2016. The relationship of endotoxaemia to peripheral and central nervous system inflammatory responses in Human African Trypanosomiasis. https://www.cambridge.org/core/journals/parasitology/article/relationship-of-endotoxaemia-to-peripheral-and-central-nervous-system-inflammatory-responses-in-human-african-trypanosomiasis/7EF81EF68573B22A51610765128B4B7E
Lauw FN, et al. 2000. Proinflammatory Effects of IL-10 During Human Endotoxemia. https://journals.aai.org/jimmunol/article/165/5/2783/33202
Chua TH and Takano A. 2022. Pathological Findings in COVID-19 and Non-COVID-19 Vaccine-Associated Lymphadenopathy: A Systematic Review. https://www.mdpi.com/2077-0383/11/21/6290/htm
Ho TC, et al. 2023. Immune Response Related to Lymphadenopathy Post COVID-19 Vaccination. https://www.mdpi.com/2076-393X/11/3/696
Goldman S, et al. Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report. https://www.frontiersin.org/articles/10.3389/fmed.2021.798095/full
Masab M, et al. 2022. Kikuchi Disease. https://www.ncbi.nlm.nih.gov/books/NBK430830/
Hassan M, et al. 2009. Kikuchi-Fujimoto Disease: Diagnostic Dilemma and the Role of Immunohistochemistry. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299190/